Quiero saber acerca de...

Federal Register / Vol. 86, No. 232 / Tuesday, December 7, 2021 / Proposed Rules 50 2-2-4-butoxybenzyl-5-nitro-1H-benzimidazol-1-yl-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other name: butonitazene
51 2-2-4-ethoxybenzyl-1H-benzimidazol-1-yl-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other names: etodesnitazene; etazene
52 N,N-diethyl-2-2-4-fluorobenzyl-5-nitro-1H-benzimidazol-1-ylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other name: flunitazene
53 N,N-diethyl-2-2-4-methoxybenzyl-1H-benzimidazol-1-ylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other name: metodesnitazene
54 N,N-diethyl-2-2-4-methoxybenzyl-5-nitro-1H-benzimidazol-1-ylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other name: metonitazene
55 2-4-ethoxybenzyl-5-nitro-1-2-pyrrolidin-1-ylethyl-1H-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other names: N-pyrrolidino etonitazene; etonitazepyne
56 N,N-diethyl-2-5-nitro-2-4-propoxybenzyl-1H-benzimidazol-1-ylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers Other name: protonitazene
Anne Milgram, Administrator.
FR Doc. 202126263 Filed 12621; 8:45 am BILLING CODE 441009P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration 21 CFR Part 1308
Docket No. DEA568

Schedules of Controlled Substances:
Placement of Methoxetamine MXE in Schedule I
Drug Enforcement Administration, Department of Justice.
ACTION: Notice of proposed rulemaking.
AGENCY:

The Drug Enforcement Administration proposes placing 2ethylamino-2-3methoxyphenylcyclohexan-1-one methoxetamine, MXE, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. This action is being taken to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I
controlled substances on persons who handle manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess, or propose to handle, methoxetamine.
DATES: Comments must be submitted electronically or postmarked on or before February 7, 2022.
Interested persons may file a request for hearing or waiver of hearing pursuant to 21 CFR 1308.44 and in accordance with 21 CFR 1316.45 and/or 1316.47, as applicable. Requests for
lotter on DSK11XQN23PROD with PROPOSALS1

SUMMARY:

VerDate Sep<11>2014

16:37 Dec 06, 2021

Jkt 256001

hearing and waivers of an opportunity for a hearing or to participate in a hearing, together with a written statement of position on the matters of fact and law asserted in the hearing, must be received on or before January 6, 2022.
ADDRESSES: Interested persons may file written comments on this proposal in accordance with 21 CFR 1308.43g. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. To ensure proper handling of comments, please reference Docket No. DEA568 on all electronic and written correspondence, including any attachments.
Electronic comments: DEA
encourages commenters to submit all comments electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https www.regulations.gov and follow the on-line instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number. Submitted comments are not instantaneously available for public view on regulations.gov. If you have received a Comment Tracking Number, you have submitted your comment successfully and there is no need to resubmit the same comment.
Paper comments: Paper comments that duplicate electronic submissions are not necessary and are discouraged.
Should you wish to mail a paper comment in lieu of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152.
Hearing requests: All requests for a hearing and waivers of participation, together with a written statement of position on the matters of fact and law asserted in the hearing, must be sent to:

PO 00000

Frm 00007

Fmt 4702

Sfmt 4702

69187

9654
9665
9656
9664
9657
9658
9659

Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing and waivers of participation should also be sent to: 1 Drug Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and 2 Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT:
Terrence L. Boos, Drug & Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration; Telephone: 571 362
3249.
SUPPLEMENTARY INFORMATION:

Posting of Public Comments All comments received in response to this docket are considered part of the public record. The Drug Enforcement Administration DEA will make comments available, unless reasonable cause is given, for public inspection online at https www.regulations.gov.
Such information includes personal identifying information such as your name, address, etc. voluntarily submitted by the commenter. The Freedom of Information Act applies to all comments received. If you want to submit personal identifying information such as your name, address, etc. as part of your comment, but do not want DEA to make it publicly available, you must include the phrase PERSONAL
IDENTIFYING INFORMATION in the first paragraph of your comment. You must also place all of the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted.
If you want to submit confidential business information as part of your comment, but do not want DEA to make it publicly available, you must include the phrase CONFIDENTIAL BUSINESS
INFORMATION in the first paragraph of your comment. You must also
E:FRFM07DEP1.SGM

07DEP1